ArticlePharmaceuticals (Basel, Switzerland)2014

Involvement of HDAC1 and HDAC3 in the Pathology of Polyglutamine Disorders: Therapeutic Implications for Selective HDAC1/HDAC3 Inhibitors.

Elizabeth A ThomasPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.